Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) has earned an average recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is GBX 2,085.83.
HIK has been the topic of several recent research reports. Citigroup raised their target price on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Berenberg Bank lifted their price objective on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,025 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, September 25th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th.
View Our Latest Stock Report on Hikma Pharmaceuticals
Insiders Place Their Bets
In related news, insider Tobias Hestler purchased 7,500 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of GBX 1,648 per share, with a total value of £123,600. Company insiders own 22.26% of the company’s stock.
Hikma Pharmaceuticals Stock Performance
Shares of LON:HIK opened at GBX 1,676 on Friday. The business has a fifty day moving average of GBX 1,611.73 and a 200-day moving average of GBX 1,529.02. The firm has a market cap of £3.47 billion, a PE ratio of 9.52, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98. Hikma Pharmaceuticals has a twelve month low of GBX 1,187 and a twelve month high of GBX 1,865.
About Hikma Pharmaceuticals
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.
Featured Articles
- Five stocks we like better than Hikma Pharmaceuticals
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
